Siemens Fonds Invest GmbH Makes New $603,000 Investment in DaVita Inc. (NYSE:DVA)

Siemens Fonds Invest GmbH purchased a new position in shares of DaVita Inc. (NYSE:DVA - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 4,035 shares of the company's stock, valued at approximately $603,000.

Other hedge funds also recently bought and sold shares of the company. Assenagon Asset Management S.A. lifted its holdings in DaVita by 201.7% during the 4th quarter. Assenagon Asset Management S.A. now owns 74,617 shares of the company's stock worth $11,159,000 after buying an additional 49,885 shares in the last quarter. Crossmark Global Holdings Inc. boosted its stake in shares of DaVita by 19.1% during the fourth quarter. Crossmark Global Holdings Inc. now owns 30,769 shares of the company's stock worth $4,601,000 after buying an additional 4,942 shares during the period. Nisa Investment Advisors LLC raised its holdings in DaVita by 10.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 40,500 shares of the company's stock worth $6,057,000 after purchasing an additional 3,680 shares in the last quarter. Janney Montgomery Scott LLC increased its holdings in shares of DaVita by 1.7% in the 4th quarter. Janney Montgomery Scott LLC now owns 25,020 shares of the company's stock valued at $3,742,000 after purchasing an additional 429 shares in the last quarter. Finally, Secure Asset Management LLC acquired a new stake in DaVita in the fourth quarter valued at $208,000. Hedge funds and other institutional investors own 90.12% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on DVA. Cowen restated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Barclays boosted their price target on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Tuesday, February 18th. Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a research note on Friday, April 25th. Truist Financial cut their target price on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research note on Monday. Finally, Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a research note on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $164.50.

DaVita Trading Down 0.8%

DaVita stock traded down $1.10 during trading on Friday, reaching $137.42. The company had a trading volume of 124,986 shares, compared to its average volume of 826,239. DaVita Inc. has a 12-month low of $131.44 and a 12-month high of $179.60. The stock's 50 day moving average price is $145.54 and its two-hundred day moving average price is $153.41. The firm has a market capitalization of $10.38 billion, a price-to-earnings ratio of 12.80, a PEG ratio of 1.07 and a beta of 1.14. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, beating analysts' consensus estimates of $1.75 by $0.25. The firm had revenue of $3.22 billion for the quarter, compared to analysts' expectations of $3.22 billion. DaVita had a net margin of 7.31% and a return on equity of 115.48%. DaVita's revenue was up 5.0% compared to the same quarter last year. During the same period in the previous year, the company posted $2.26 earnings per share. As a group, equities analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.